Literature DB >> 3743145

Reperfusion arrhythmias during coronary reperfusion therapy in man. Clinical and angiographic correlations.

T A Buckingham, J E Devine, R M Redd, H L Kennedy.   

Abstract

We hypothesized that patients suffering acute myocardial infarction who have reperfusion arrhythmias (RPA) during intracoronary streptokinase infusion (ICSK) would have different clinical and angiographic characteristics and a larger infarction size than those who achieved reperfusion without RPA. Of 35 patients who received intracoronary streptokinase, 27 had successful reperfusion documented by angiography. Successful reperfusion was accompanied by RPA in eight patients and no RPA in 19 patients. RPA included episodes of ventricular tachycardia in one, idioventricular rhythm in four, junctional bradycardia in one, or AV block in two patients which occurred at the time of reperfusion. Myocardial infarction size was calculated using creatine kinase-MB (CK-MB) isoenzyme time activity curves using standard methods. The mean CK-MB g equivalents (eq) for those with RPA was 71 +/- 25 (+/- 1 SD) and for those with no RPA was 45 +/- 24 (p less than .04). In patients with RPA, ejection fraction rose 5 +/- 14 percentage points before discharge, but fell 10 +/- 13 points in those with RPA (p less than .03). There was no difference between groups in total dose of streptokinase, final degree of stenosis of the affected vessel, reocclusion rate, or time from onset of symptoms to reperfusion. We conclude that patients suffering acute myocardial infarction who have RPA during ICSK in most cases have a larger infarction site or a more "stunned myocardium," as indicated by greater CK-MB release and fall in ejection fraction which is not due to increased time of ischemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3743145     DOI: 10.1378/chest.90.3.346

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  French multicenter trial of anistreplase versus heparin in acute myocardial infarction.

Authors:  H Lardoux; Y Louvard; D de Vernejoul; C Picot; M Baudet; M Hiltgen; M Houplon; J Ponsonnaille; M Richard; R Luccioni
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

2.  Controlled regional hypoperfusion in Langendorff heart preparations.

Authors:  Luther Swift; Brian Martell; Vishal Khatri; Ara Arutunyan; Narine Sarvazyan; Matthew Kay
Journal:  Physiol Meas       Date:  2008-02-05       Impact factor: 2.833

3.  Incidence and risk factors of ventricular fibrillation before primary angioplasty in patients with first ST-elevation myocardial infarction: a nationwide study in Denmark.

Authors:  Reza Jabbari; Thomas Engstrøm; Charlotte Glinge; Bjarke Risgaard; Javad Jabbari; Bo Gregers Winkel; Christian Juhl Terkelsen; Hans-Henrik Tilsted; Lisette Okkels Jensen; Mikkel Hougaard; Stephanie E Chiuve; Frants Pedersen; Jesper Hastrup Svendsen; Stig Haunsø; Christine M Albert; Jacob Tfelt-Hansen
Journal:  J Am Heart Assoc       Date:  2015-01-05       Impact factor: 5.501

4.  Impact of Late Ventricular Arrhythmias on Cardiac Mortality in Patients with Acute Myocardial Infarction.

Authors:  Takuma Takada; Koki Shishido; Takahiro Hayashi; Shohei Yokota; Hirokazu Miyashita; Hiroaki Yokoyama; Takashi Nishimoto; Tomoki Ochiai; Noriaki Moriyama; Kazuki Tobita; Shingo Mizuno; Futoshi Yamanaka; Masato Murakami; Yutaka Tanaka; Saeko Takahashi; Shigeru Saito
Journal:  J Interv Cardiol       Date:  2019-07-08       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.